These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 1612502)

  • 1. Intraperitoneal radioimmunotherapy of refractory ovarian carcinoma utilizing iodine-131-labeled monoclonal antibody OC125.
    Muto MG; Finkler NJ; Kassis AI; Howes AE; Anderson LL; Lau CC; Zurawski VR; Weadock K; Tumeh SS; Lavin P
    Gynecol Oncol; 1992 Jun; 45(3):265-72. PubMed ID: 1612502
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I study of 90Y-labeled B72.3 intraperitoneal administration in patients with ovarian cancer: effect of dose and EDTA coadministration on pharmacokinetics and toxicity.
    Rosenblum MG; Verschraegen CF; Murray JL; Kudelka AP; Gano J; Cheung L; Kavanagh JJ
    Clin Cancer Res; 1999 May; 5(5):953-61. PubMed ID: 10353726
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I clinical evaluation of a new murine monoclonal antibody (Mu-9) against colon-specific antigen-p for targeting gastrointestinal carcinomas.
    Sharkey RM; Goldenberg DM; Vagg R; Pawlyk D; Wong GY; Siegel JA; Murthy S; Levine GM; Izon D; Gascon P
    Cancer; 1994 Feb; 73(3 Suppl):864-77. PubMed ID: 8306272
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospects of radioimmunotherapy in epithelial ovarian cancer: results with iodine-131-labeled murine and humanized MN-14 anti-carcinoembryonic antigen monoclonal antibodies.
    Juweid M; Swayne LC; Sharkey RM; Dunn R; Rubin AD; Herskovic T; Goldenberg DM
    Gynecol Oncol; 1997 Dec; 67(3):259-71. PubMed ID: 9441773
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase-I/II radio-immunotherapy study with Iodine-131-labeled anti-CEA monoclonal antibody F6 F(ab')2 in patients with non-resectable liver metastases from colorectal cancer.
    Ychou M; Pelegrin A; Faurous P; Robert B; Saccavini JC; Guerreau D; Rossi JF; Fabbro M; Buchegger F; Mach JP; Artus JC
    Int J Cancer; 1998 Feb; 75(4):615-9. PubMed ID: 9466665
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intraperitoneal radiolabeled OC 125 in patients with advanced ovarian cancer.
    Finkler NJ; Muto MG; Kassis AI; Weadock K; Tumeh SS; Zurawski VR; Knapp RC
    Gynecol Oncol; 1989 Sep; 34(3):339-44. PubMed ID: 2767526
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intraperitoneal radioimmunotherapy for ovarian cancer: pharmacokinetics, toxicity, and efficacy of I-131 labeled monoclonal antibodies.
    Stewart JS; Hird V; Snook D; Sullivan M; Hooker G; Courtenay-Luck N; Sivolapenko G; Griffiths M; Myers MJ; Lambert HE
    Int J Radiat Oncol Biol Phys; 1989 Feb; 16(2):405-13. PubMed ID: 2921145
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human anti-murine antibody responses in ovarian cancer patients undergoing radioimmunotherapy with the murine monoclonal antibody OC-125.
    Muto MG; Finkler NJ; Kassis AI; Lepisto EM; Knapp RC
    Gynecol Oncol; 1990 Aug; 38(2):244-8. PubMed ID: 2387541
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic effect of a radiolabeled monoclonal antibody on human ovarian cancer xenograft in nude mice.
    Manetta A; Satyaswaroop PG; Hamilton T; Ozols R; Mortel R
    Gynecol Oncol; 1989 Mar; 32(3):368-70. PubMed ID: 2920960
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of cytotoxicity of 131I-labelled OC125 F(ab')2 on human epithelial ovarian cancer cell lines.
    Schneider-Gädicke E; Humm JL; Lau CC; Macklis RM; Bastert G; Knapp RC
    Radiother Oncol; 1992 Mar; 23(3):150-9. PubMed ID: 1574594
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of human antimurine antibody on CA 125 levels in patients with ovarian cancer undergoing radioimmunotherapy or immunoscintigraphy with murine monoclonal antibody OC 125.
    Muto MG; Lepisto EM; Van den Abbeele AD; Knapp RC; Kassis AI
    Am J Obstet Gynecol; 1989 Nov; 161(5):1206-12. PubMed ID: 2686446
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the pharmacokinetics, biodistribution and dosimetry of monoclonal antibodies OC125, OV-TL 3, and 139H2 as IgG and F(ab')2 fragments in experimental ovarian cancer.
    Molthoff CF; Pinedo HM; Schlüper HM; Nijman HW; Boven E
    Br J Cancer; 1992 May; 65(5):677-83. PubMed ID: 1586596
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I/II study of iodine 131-labeled monoclonal antibody A33 in patients with advanced colon cancer.
    Welt S; Divgi CR; Kemeny N; Finn RD; Scott AM; Graham M; Germain JS; Richards EC; Larson SM; Oettgen HF
    J Clin Oncol; 1994 Aug; 12(8):1561-71. PubMed ID: 8040668
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase I trial of a rhenium 186-labeled monoclonal antibody administered intraperitoneally in ovarian carcinoma: toxicity and clinical response.
    Jacobs AJ; Fer M; Su FM; Breitz H; Thompson J; Goodgold H; Cain J; Heaps J; Weiden P
    Obstet Gynecol; 1993 Oct; 82(4 Pt 1):586-93. PubMed ID: 8377986
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase II study of intraperitoneal radioimmunotherapy with iodine-131-labeled monoclonal antibody OC-125 in patients with residual ovarian carcinoma.
    Mahé MA; Fumoleau P; Fabbro M; Guastalla JP; Faurous P; Chauvot P; Chetanoud L; Classe JM; Rouanet P; Chatal JF
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3249s-3253s. PubMed ID: 10541371
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Distribution and pharmacokinetics of radiolabeled monoclonal antibody OC 125 after intravenous and intraperitoneal administration in gynecologic tumors.
    Haisma HJ; Moseley KR; Battaile A; Griffiths TC; Knapp RC
    Am J Obstet Gynecol; 1988 Oct; 159(4):843-8. PubMed ID: 3177533
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radioimmunotherapy with intravenously administered 131I-labeled chimeric monoclonal antibody MOv18 in patients with ovarian cancer.
    van Zanten-Przybysz I; Molthoff CF; Roos JC; Plaizier MA; Visser GW; Pijpers R; Kenemans P; Verheijen RH
    J Nucl Med; 2000 Jul; 41(7):1168-76. PubMed ID: 10914906
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I dose-escalation trial of iodine 131-labeled monoclonal antibody OKB7 in patients with non-Hodgkin's lymphoma.
    Czuczman MS; Straus DJ; Divgi CR; Graham M; Garin-Chesa P; Finn R; Myers J; Old LJ; Larson SM; Scheinberg DA
    J Clin Oncol; 1993 Oct; 11(10):2021-9. PubMed ID: 8410126
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intraperitoneal α-Emitting Radioimmunotherapy with
    Hallqvist A; Bergmark K; Bäck T; Andersson H; Dahm-Kähler P; Johansson M; Lindegren S; Jensen H; Jacobsson L; Hultborn R; Palm S; Albertsson P
    J Nucl Med; 2019 Aug; 60(8):1073-1079. PubMed ID: 30683761
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intrathecal 131I-labeled antitenascin monoclonal antibody 81C6 treatment of patients with leptomeningeal neoplasms or primary brain tumor resection cavities with subarachnoid communication: phase I trial results.
    Brown MT; Coleman RE; Friedman AH; Friedman HS; McLendon RE; Reiman R; Felsberg GJ; Tien RD; Bigner SH; Zalutsky MR; Zhao XG; Wikstrand CJ; Pegram CN; Herndon JE; Vick NA; Paleologos N; Fredericks RK; Schold SC; Bigner DD
    Clin Cancer Res; 1996 Jun; 2(6):963-72. PubMed ID: 9816257
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.